Athersys (ATHX) is a bio-pharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. ATHX is developing MultiStem, a patented adult-derived “off-the-shelf” stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. (www.athersys.com)
Read more…
Opexa Therapeutics develops of patient-specific cellular therapies for the treatment of autoimmune diseases. OPXA is developing Tovaxin®, an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin® is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections triggering a potent immune response against specific subsets of autoreactive T-cells known to attack myelin, believed to be a primary cause of MS attacks and nervous system damage. Read more…
Neuralstem is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine Read more…
National Institutes of Health (NIH) director Francis Collins approved 27 more human embryonic stem cell lines as eligible for federal funding on 12/14/09, bringing the total number of new lines to 40 — almost double the number of previously okayed lines under the administration of former President George W. Bush. Read more…
NeoStem is engaged in the business of developing stem cell therapies, pursuing anti-aging initiatives and is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. (www.neostem.com) Read more…
Opexa Therapeutics develops of patient-specific cellular therapies for the treatment of autoimmune diseases. Reiterating from our 12/2/09 post – According to the National Multiple Sclerosis Society, MS affects approximately 2.5 M individuals worldwide. Industry experts estimated the global sales of MS therapeutics at approximately $6 B. Read more…
Interim RESTORE 2 results presented (12/12/09) demonstrate that Read more…
Neuralstem is a biotechnology company, focuses on developing and commercializing human neural stem cell technology in the field of regenerative medicine primarily in the United States. Read more…
Aastrom is a leader in regenerative medicine developing autologous cell products for the treatment of severe, chronic cardiovascular diseases. ASTM’s proprietary Tissue Repair Cell (TRC) technology expands the numbers of stem and early progenitor cells from a small amount of bone marrow collected from the patient.
Read more…
A new era in embryonic stem cell research is evolving Read more…